EUVIMEDEUVIMED entdecken
Crossref

The Future of Biomarkers Tests and Genomic Medicine in Global Organ Disease

Martins IJ

Microbiology & Infectious Diseases · 2017

DOI: 10.33425/2639-9458.1009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology & Infectious Diseases, 2017. Verfasst von Martins IJ.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Editorial Interests in global organ diseases have accelerated with links between nonalcoholic fatty liver disease (NAFLD) and various chronic diseases with relevance to the metabolic syndrome and neurodegenerative diseases. Early diagnosis of global organ disease involve genomic, lipidomic and proteomic biomarker tests that may diagnose early neuron dysfunction with the prevention of various organ diseases [1]. Diet and nutrition are closely linked to accelerated aging and may allow biomarker tests to provide adequate information with relevance to the immune system dysfunction and the severity of chronic diseases. In spite of various biomarker tests and analyte measurements for chronic diseases such as obesity and diabetes abnormal nuclear-mitochondria interactions [2] persist with inflammation involved in the induction of programmed cell death.

Zitieren

APA

IJ, M. (2017). The Future of Biomarkers Tests and Genomic Medicine in Global Organ Disease. Microbiology & Infectious Diseases. https://doi.org/10.33425/2639-9458.1009

Vancouver

IJ M. The Future of Biomarkers Tests and Genomic Medicine in Global Organ Disease. Microbiology & Infectious Diseases. 2017. doi:10.33425/2639-9458.1009

BibTeX
@article{IJ2017,
  author = {IJ, Martins},
  title = {The Future of Biomarkers Tests and Genomic Medicine in Global Organ Disease},
  journal = {Microbiology & Infectious Diseases},
  year = {2017},
  doi = {10.33425/2639-9458.1009}
}
Kostenlos starten →